Patents by Inventor Rango Dietrich

Rango Dietrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9468598
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: October 18, 2016
    Assignee: AstraZeneca AB
    Inventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
  • Publication number: 20150290178
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
    Type: Application
    Filed: June 5, 2015
    Publication date: October 15, 2015
    Inventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
  • Publication number: 20150290180
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
    Type: Application
    Filed: June 9, 2015
    Publication date: October 15, 2015
    Inventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
  • Publication number: 20150290179
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
    Type: Application
    Filed: June 9, 2015
    Publication date: October 15, 2015
    Inventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
  • Patent number: 8758817
    Abstract: Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: June 24, 2014
    Assignee: Takeda GmbH
    Inventors: Rango Dietrich, Isabel Anstett-Klein, Marc Schiller, Hartmut Ney, Manfred Hartmann, Sabine Schäfer-Preuss
  • Patent number: 8754108
    Abstract: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: June 17, 2014
    Assignee: Takeda, GmbH
    Inventors: Rudolf Linder, Rango Dietrich
  • Patent number: 8703192
    Abstract: Dosage forms for the oral administration of the magnesium salt of pantoprazole are described.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: April 22, 2014
    Assignee: Takeda GmbH
    Inventors: Isabel Anstett-Klein, Rango Dietrich, Hartmut Ney, Marc Schiller, Sabine Schaefer-Preuss, Manfred Hartmann
  • Publication number: 20140031397
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 30, 2014
    Applicant: Takeda GmbH
    Inventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
  • Publication number: 20140031396
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP binder.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 30, 2014
    Applicant: Takeda GmbH
    Inventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
  • Publication number: 20130345265
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
    Type: Application
    Filed: April 30, 2013
    Publication date: December 26, 2013
    Applicant: Takeda GmbH
    Inventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
  • Patent number: 8465767
    Abstract: The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: June 18, 2013
    Assignee: Takeda GmbH
    Inventors: Rango Dietrich, Hartmut Ney
  • Publication number: 20130131123
    Abstract: An immediate release solid dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor, comprising a PDE 4 inhibitor that is N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast) or a salt thereof, and one or more suitable pharmaceutical excipients; wherein said dosage form contains 500 ?g of the roflumilast or salt thereof.
    Type: Application
    Filed: January 11, 2013
    Publication date: May 23, 2013
    Applicant: Nycomed GmbH
    Inventors: Rango DIETRICH, Hartmut NEY, Klaus EISTETTER
  • Patent number: 8431154
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: April 30, 2013
    Assignee: Takeda GmbH
    Inventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
  • Publication number: 20110251244
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
    Type: Application
    Filed: January 18, 2011
    Publication date: October 13, 2011
    Applicant: NYCOMED GMBH
    Inventors: Rango Dietrich, Hartmut Ney, Klaus Eistetter
  • Patent number: 7988999
    Abstract: The present invention relates to the field of pharmaceutical technology and describes a pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient, in particular an acid-labile proton pump inhibitor. The invention also relates to processes for producing the paste. The paste is particularly suitable for administering acid-labile active ingredients to animals or to people who have difficulty taking solid dosage forms such as tablets or capsules.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: August 2, 2011
    Assignee: NYCOMED GmbH
    Inventors: Rango Dietrich, Rudolf Linder
  • Publication number: 20110171303
    Abstract: Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described.
    Type: Application
    Filed: March 23, 2011
    Publication date: July 14, 2011
    Applicant: NYCOMED GMBH
    Inventors: Rango DIETRICH, Isabel ANSTETT-KLEIN, Marc SCHILLER, Hartmut NEY, Manfred HARTMANN, Sabine SCHÄFER-PREUSS
  • Patent number: 7951397
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: May 31, 2011
    Assignee: Nycomed GmbH
    Inventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
  • Patent number: 7951398
    Abstract: The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohols, triglycerides, partial triglycerides and fatty acid esters.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: May 31, 2011
    Assignee: Nycomed GmbH
    Inventors: Rango Dietrich, Rudolf Linder, Hartmut Ney
  • Publication number: 20110060016
    Abstract: Disclosed is a method of treatment of COPD by oral administration of roflumilast.
    Type: Application
    Filed: September 7, 2010
    Publication date: March 10, 2011
    Applicant: NYCOMED GMBH
    Inventors: Rango Dietrich, Hartmut Ney, Klaus Eistetter
  • Patent number: 7794752
    Abstract: Novel administration forms and preparations for acid-labile active compounds are described. The novel administration forms contain individual active compound units, the active compound being present in the active compound units in a matrix made of a mixture comprising at least one fatty alcohol and at least one solid paraffin, in a matrix made of a mixture of a triglyceride and at least one solid paraffin or in a matrix made of a mixture comprising at least one fatty acid ester and at least one solid paraffin. In particular, the active compound units are microspheres which can be produced by prilling.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: September 14, 2010
    Assignee: NYCOMED GmbH
    Inventors: Rango Dietrich, Rudolf Linder